Simponi Related Published Studies
Well-designed clinical trials related to Simponi (Golimumab)
The effect of intravenous golimumab on health-related quality of life in
rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. [2014]
Safety and efficacy of golimumab in Chinese patients with active ankylosing
spondylitis: 1-year results of a multicentre, randomized, double-blind,
placebo-controlled phase III trial. [2014]
Golimumab reduces disease activity of rheumatoid arthritis for 1 year and
strongly inhibits radiographic progression in Japanese patients: partial but
detailed results of the GO-FORTH and GO-MONO studies. [2013]
Comparison of three enthesitis indices in a multicentre, randomized,
placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). [2013]
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis
irrespective of its anti-inflammatory effects: disassociation of the link between
inflammation and destruction. [2012]
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis:
104-week results of the GO-RAISE study. [2012]
The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. [2011.05]
Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. [2011.05]
Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. [2010.09]
Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial. [2010.09]
Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. [2010.07]
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. [2010.06]
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. [2010.04]
Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. [2010.03]
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. [2010]
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered
intravenously in patients with active rheumatoid arthritis: Forty-eight-week
efficacy and safety results of a phase III randomized, double-blind,
placebo-controlled study. [2010]
Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. [2009.09]
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. [2009.08]
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. [2009.07.18]
E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. [2009.07]
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. [2009.06]
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. [2009.04]
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. [2008.11]
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. [2008.04]
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. [2007.03]
Well-designed clinical trials possibly related to Simponi (Golimumab)
The comparative safety of tumor necrosis factor inhibitors in rheumatoid
arthritis: a meta-analysis update of 44 trials. [2014]
A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. [2011.10]
Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. [2011.08]
The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. [2011.01]
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. [2009.04.01]
Other research related to Simponi (Golimumab)
Comparison of composite measures of disease activity in psoriatic arthritis using
data from an interventional study with golimumab. [2014]
Comprehensive tuberculosis screening program in patients with inflammatory
arthritides treated with golimumab, a human anti-tumor necrosis factor antibody,
in Phase III clinical trials. [2013]
Treatment of psoriatic arthritis with tumor necrosis factor inhibitors:
longer-term outcomes including enthesitis and dactylitis with golimumab treatment
in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). [2012]
Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. [2011.12]
Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. [2011.12]
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. [2011.11.29]
Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. [2011.11.25]
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. [2011.11.11]
Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. [2011.11]
Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. [2011.10.28]
Golimumab and immunogenicity? 2010 and beyond. [2011.04]
Golimumab - a new tool in the armoury against inflammatory arthritis. [2011.03]
Dermatologic adverse events: golimumab, friend or foe? [2011.01]
Golimumab for the treatment of psoriatic arthritis. [2011]
The effects of golimumab on radiographic progression in rheumatoid arthritis:
results of randomized controlled studies of golimumab before methotrexate therapy
and golimumab after methotrexate therapy. [2011]
Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. [2010.09]
A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. [2010.08]
Golimumab therapy of rheumatoid arthritis: an overview. [2010.08]
Population Approach for Exposure-Response Modeling of Golimumab in Patients With Rheumatoid Arthritis. [2010.07.09]
The efficacy and safety of golimumab in the treatment of arthritis. [2010.07]
Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. [2010.06.15]
Golimumab for rheumatoid arthritis: a systematic review. [2010.06]
Golimumab for rheumatoid arthritis. [2010.01.20]
Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. [2010.01]
Population pharmacokinetics of golimumab in patients with ankylosing spondylitis:
impact of body weight and immunogenicity. [2010]
Golimumab reduces sleep disturbance in patients with active ankylosing
spondylitis: results from a randomized, placebo-controlled trial. [2010]
The efficacy and safety of golimumab in the treatment of arthritis. [2010]
Golimumab in patients with active rheumatoid arthritis despite methotrexate
therapy: 52-week results of the GO-FORWARD study. [2010]
Golimumab for rheumatoid arthritis: a systematic review. [2010]
Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in
healthy Japanese and Caucasian male subjects. [2010]
Tocilizumab for rheumatoid arthritis. [2010]
Subcutaneous bioavailability of golimumab at 3 different injection sites in
healthy subjects. [2010]
Golimumab. [2009.09]
Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. [2009.08]
Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. [2009]
Golimumab, a fully human monoclonal antibody against TNFalpha. [2008.08]
Other possibly related research studies
Gateways to clinical trials. [2010.04]
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. [2010.06]
Safety and efficacy of the tumor necrosis factor antagonists. [2010.03]
Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. [2010.03]
Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. [2010]
[Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis] [2009.12]
Novel TNF antagonists for the treatment of rheumatoid arthritis. [2010.01]
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs] [2009.04]
Gateways to clinical trials. [2009.10]
TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. [2010.04]
Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules. [2009.07]
Gateways to clinical trials. [2009.07]
Update on the treatment of peripheral arthritis in psoriatic arthritis. [2009.08]
[Biologic therapies in chronic inflammatory bowel diseases] [2009.05]
[Biological therapies in rheumatology] [2009.05]
[New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis] [2009.06]
Biological therapy of inflammatory bowel disease. [2009.01]
Prospective new biological therapies for rheumatoid arthritis. [2009.12]
[Biologic therapies in the treatment of psoriasis] [2009.05]
New biologics for psoriasis and psoriatic arthritis. [2009.01]
Biologic agents for rheumatoid arthritis: 2008 and beyond. [2009.01]
Emerging therapeutics for rheumatoid arthritis. [2008]
Gateways to clinical trials. [2008.05]
Biologic agents in rheumatoid arthritis: an update for managed care professionals. [2011.11]
A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. [2011.12]
Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. [2011.12]
A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. [2011.09.29]
Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. [2011.12]
Associations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritis. [2011.11]
Indirect comparison of biological treatments in refractory rheumatoid arthritis. [2011.08.10]
Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. [2011.09]
Cytokine modulators in the treatment of sarcoidosis. [2011.12]
Advances in rheumatology: new targeted therapeutics. [2011.05.25]
[Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. [2011.06.05]
Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. [2011.04]
|